

Comunicação sobre TRANSAÇÕES ENTRE PARTES RELACIONADAS

Dexco S.A. (B3: DXCO3) ("Companhia"), em observância ao disposto na Resolução CVM nº 80/22 (Anexo F), comunica a realização das seguintes transações entre partes relacionadas:

Nome das Partes relacionadas	Dexco S.A. (Vendedora) e Mysa S.A. (Compradora).
Relações com o emissor	A Dexco S.A. possui 14,19% das ações do capital social da Mysa S.A. e tem o direito de indicar um membro efetivo e um suplente em seu Conselho de Administração.
Período das transações	01/06/2026 a 27/09/2026.
Objeto do contrato	Vendas de produtos dos segmentos Deca e Revestimentos, sujeitas a condições e políticas próprias de cada segmento.
Principais termos e condições e montante envolvido	Transações comerciais recorrentes de fornecimento de produtos Deca e Revestimentos, para venda no mercado interno. No período de 01 de junho a 27 de setembro de 2026, as vendas acumuladas atingiram o montante de R\$ 53.461.451,01, se consideradas as vendas de produtos dos segmentos Deca e Revestimentos em conjunto. As transações referentes a cada um desses segmentos não são correlatas entre si, tendo sido a divulgação desta comunicação realizada pela Companhia apenas por se tratar de uma mesma parte relacionada.
Justificativa das razões pelas quais a administração do emissor considera que a transação observou condições comutativas ou prevê pagamento compensatório adequado	A administração da Companhia entende que as transações comerciais com Mysa S.A. observaram as condições comutativas e preveem pagamento compensatório adequado, visto que as transações de vendas foram efetuadas em condições normais de mercado, respeitando a política comercial da Companhia. Essas transações foram examinadas pelo Comitê para Avaliação de Transações com Partes Relacionadas da Companhia, integrado e presidido por conselheiros independentes, que emitiu manifestação favorável à sua realização, por estarem em condições equitativas de mercado e em conformidade com a Política de Transações com Partes Relacionadas da Companhia.
Eventual participação da contraparte, seus sócios ou administradores no processo de decisão do emissor acerca da transação ou	A Companhia indica um membro do Conselho de Administração e seu suplente na contraparte Mysa S.A. Tal administrador

Dexco

CNPJ nº 97.837.181/0001-47
Companhia Aberta

negociação da transação como representantes do emissor, descrevendo essa participação

e seu suplente são executivos da Companhia, que não participaram do processo de negociação e não fazem parte do Comitê para Avaliação de Transações com Partes Relacionadas, que recomendou a aprovação das transações.

São Paulo (SP), 05 de outubro de 2026.

Guilherme Setubal Souza e Silva
Diretor de Relações com Investidores, Institucionais e ESG

ANNOUNCEMENT ON TRANSACTIONS BETWEEN RELATED PARTIES

Dexco S.A. (B3: DXCO3) (“Company”), pursuant to the provision in CVM Resolution 80/22 (Attachment F), announces the execution of the following transactions between related parties:

Name of the Related Parties	Dexco S.A. (Seller) and Mysa S.A (Purchaser).
Relations with the issuer	Dexco S.A. owns 14.19% of the share capital of Mysa S.A. and has the right to appoint one effective member and one alternate member to its Board of Directors.
Transactions period	From June 01, 2026 to September 27, 2026.
Contract purpose	Sales of Deca products and ceramic tiles products (subject to the conditions and policies specific to each segment).
Principal terms and conditions and amounts involved	Recurring commercial transactions for the supply of Deca products and ceramic tiles products for sale in the domestic market. In the period from June 01, 2026 to September 27, 2026, accumulated sales amounted to R\$ 53,461,451.01, considering the sales of products from the Deca and ceramic tiles segments are taken together. The transactions relating to each of these segments are not related to each other, and the Company has only disclosed this announcement because they involve the same related party.
Justification of the reasons for which the issuer’s management deems the transaction to have been conducted on the basis of arm’s-length conditions or provides for adequate compensatory payment	The Company's management believes that the commercial transactions with Mysa S.A. complied with the commutative conditions and provided for adequate compensatory payment, since the sales transactions were carried out under normal market conditions, respecting Dexco S.A.'s respective commercial policies. These transactions have been examined by the Company’s Committee for Evaluation of Transactions with Related Parties, composed of and chaired by independent directors, which issued a favorable opinion on their execution, considering that they have been executed in arms-length conditions and are in compliance with the Company’s Policy of Transactions with Related Parties.
Eventual participation of the counterparty, its partners or managers in the decision-making process of the transaction or negotiation of the transaction as	The Company appoints an effective member of the Board of Directors and an alternate member at the counterparty Mysa S.A. Such director and alternate

representatives of the issuer, describing this participation	member are executives of the Company, who did not participate in the negotiation process and are not part of the Committee for the Evaluation of Transactions with Related Parties, which recommended the approval of the transactions.
--	---

São Paulo (SP), October 05, 2026.

Guilherme Setubal Souza e Silva

Director of IR, Institutional and Governmental Relations, and ESG

ANNOUNCEMENT ON **TRANSACTIONS BETWEEN RELATED PARTIES**

Dexco S.A. (B3: DXCO3) ("Company"), pursuant to the provision in CVM Resolution 80/22 (Attachment F), announces the execution of the following transactions between related parties:

Name of the Related Parties	Dexco S.A. (Seller) and Mysa S.A (Purchaser).
Relations with the issuer	Dexco S.A. owns 14.19% of the share capital of Mysa S.A. and has the right to appoint one effective member and one alternate member to its Board of Directors.
Transactions period	From June 01, 2026 to September 27, 2026.
Contract purpose	Sales of Deca products and ceramic tiles products (subject to the conditions and policies specific to each segment).
Principal terms and conditions and amounts involved	Recurring commercial transactions for the supply of Deca products and ceramic tiles products for sale in the domestic market. In the period from June 01, 2026 to September 27, 2026, accumulated sales amounted to R\$ 53,461,451.01, considering the sales of products from the Deca and ceramic tiles segments are taken together. The transactions relating to each of these segments are not related to each other, and the Company has only disclosed this announcement because they involve the same related party.
Justification of the reasons for which the issuer's management deems the transaction to have been conducted on the basis of arm's-length conditions or provides for adequate compensatory payment	The Company's management believes that the commercial transactions with Mysa S.A. complied with the commutative conditions and provided for adequate compensatory payment, since the sales transactions were carried out under normal market conditions, respecting Dexco S.A.'s respective commercial policies. These transactions have been examined by the Company's Committee for Evaluation of Transactions with Related Parties, composed of and chaired by independent directors, which issued a favorable opinion on their execution, considering that they have been executed in arms-length conditions and are in compliance with the Company's Policy of Transactions with Related Parties.
Eventual participation of the counterparty, its partners or managers in the decision-making process of the transaction or negotiation of the transaction as	The Company appoints an effective member of the Board of Directors and an alternate member at the counterparty Mysa S.A. Such director and alternate

representatives of the issuer, describing this participation	member are executives of the Company, who did not participate in the negotiation process and are not part of the Committee for the Evaluation of Transactions with Related Parties, which recommended the approval of the transactions.
--	---

São Paulo (SP), October 05, 2026.

Guilherme Setubal Souza e Silva

Director of IR, Institutional and Governmental Relations, and ESG